Provectus Pharmaceuticals, Inc. (PVCT.OB) Commences Phase 2 Clinical Trial
Provectus Pharmaceuticals announced today that it has received approval to begin Phase 2 clinical testing of PH-10, the company’s topical drug designed to treat psoriasis. The study is intended to identify the effectiveness of PH-10 by using twenty-five subjects with moderate to severe forms of the disease. PH-10 will be applied twice weekly for up to twelve weeks to each participant’s psoriatic plaque areas. The reaction will be monitored throughout this treatment phase and a month after the end of the phase. Response will be graded using the Psoriasis Severity Index (PSI) and an investigator’s clinical assessment of Plaque Response. Changes…